TM4SF19

Across TCGA pan-cancer cohorts, TM4SF19 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM4SF19 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TM4SF19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TM4SF19 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LUSC, and KIRP are the cancer types where TM4SF19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.158	0.720	<.001	48	view →
LUSC	OS	Median	II,III,IV	0.250	0.778	.007	15	view →
KIRP	OS	Median	All	0.272	0.885	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.630	.030	4	view →
COAD	OS	Median	All	0.168	0.805	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TM4SF19–BLCA (OS)

Open the BLCA breakdown →